ORIC
ORIC Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 0 | 59.02M | $639.12M | +7 | −7 |
| Q1 2026 | 75 | +3 | 50.35M | $637.44M | +9 | −6 |
| Q4 2025 | 72 | +1 | 55.15M | $451.14M | +1 | — |
| Q3 2025 | 17 | 0 | 34.78M | $417.41M | — | — |
| Q2 2025 | 14 | +1 | 27.12M | $275.30M | +3 | −2 |
| Q1 2025 | 10 | +1 | 12.33M | $68.78M | +2 | −1 |
| Q4 2024 | 9 | -1 | 9.74M | $78.61M | — | −1 |
| Q3 2024 | 9 | 0 | 7.63M | $78.26M | +1 | −1 |
| Q2 2024 | 9 | — | 8.42M | $59.53M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 4.00M | — | $28.28M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.22M | — | $8.65M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | T. Rowe Price ✦ | 1.19M | — | $8.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 782.30K | — | $5.53M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 780.40K | — | $5.52M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 262.51K | — | $1.86M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 122.82K | — | $868,359 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 47.00K | — | $332,290 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 12.24K | — | $86,544 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 119.04M shares, $1.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13.40K sh · $181,258
Officer · 100 sh · $1,350
Officer · 500 sh · $6,752
Officer · 77.00K sh · $1.05M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology